Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma
BACKGROUNDNeoantigen-driven recognition and T cell-mediated killing contribute to tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs). Yet how diversity, frequency, and persistence of expanded neoepitope-specific CD8+ T cells derived from TIL infusion products affect patient outcome is not fully determined.METHODSUsing barcoded pMHC multimers, we provide a comprehensive mapping of CD8+ T cells recognizing neoepitopes in TIL infusion products and blood samples from 26 metastatic melanoma patients who received ACT.RESULTSWe identified 106 neoepitopes within TIL infusion products corresponding to 1.8% of all predicted neoepitopes. We observed neoepitope-specific recognition to be virtually devoid in TIL infusion products given to patients with progressive disease outcome. Moreover, we found that the frequency of neoepitope-specific CD8+ T cells in TIL infusion products correlated with increased survival and that neoepitope-specific CD8+ T cells shared with the infusion product in posttreatment blood samples were unique to responders of TIL-ACT. Finally, we found that a transcriptional signature for lymphocyte activity within the tumor microenvironment was associated with a higher frequency of neoepitope-specific CD8+ T cells in the infusion product.CONCLUSIONSThese data support previous case studies of neoepitope-specific CD8+ T cells in melanoma and indicate that successful TIL-ACT is associated with an expansion of neoepitope-specific CD8+ T cells.FUNDINGNEYE Foundation; European Research Council; Lundbeck Foundation Fellowship; Carlsberg Foundation.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
---|---|
Enthalten in: |
The Journal of clinical investigation - 132(2022), 2 vom: 18. Jan. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kristensen, Nikolaj Pagh [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antigens, Neoplasm |
---|
Anmerkungen: |
Date Completed 17.02.2022 Date Revised 17.02.2022 published: Print ClinicalTrials.gov: NCT00937625 Citation Status MEDLINE |
---|
doi: |
10.1172/JCI150535 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM333507525 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM333507525 | ||
003 | DE-627 | ||
005 | 20231225221805.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1172/JCI150535 |2 doi | |
028 | 5 | 2 | |a pubmed24n1111.xml |
035 | |a (DE-627)NLM333507525 | ||
035 | |a (NLM)34813506 | ||
035 | |a (PII)e150535 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kristensen, Nikolaj Pagh |e verfasserin |4 aut | |
245 | 1 | 0 | |a Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.02.2022 | ||
500 | |a Date Revised 17.02.2022 | ||
500 | |a published: Print | ||
500 | |a ClinicalTrials.gov: NCT00937625 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUNDNeoantigen-driven recognition and T cell-mediated killing contribute to tumor clearance following adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs). Yet how diversity, frequency, and persistence of expanded neoepitope-specific CD8+ T cells derived from TIL infusion products affect patient outcome is not fully determined.METHODSUsing barcoded pMHC multimers, we provide a comprehensive mapping of CD8+ T cells recognizing neoepitopes in TIL infusion products and blood samples from 26 metastatic melanoma patients who received ACT.RESULTSWe identified 106 neoepitopes within TIL infusion products corresponding to 1.8% of all predicted neoepitopes. We observed neoepitope-specific recognition to be virtually devoid in TIL infusion products given to patients with progressive disease outcome. Moreover, we found that the frequency of neoepitope-specific CD8+ T cells in TIL infusion products correlated with increased survival and that neoepitope-specific CD8+ T cells shared with the infusion product in posttreatment blood samples were unique to responders of TIL-ACT. Finally, we found that a transcriptional signature for lymphocyte activity within the tumor microenvironment was associated with a higher frequency of neoepitope-specific CD8+ T cells in the infusion product.CONCLUSIONSThese data support previous case studies of neoepitope-specific CD8+ T cells in melanoma and indicate that successful TIL-ACT is associated with an expansion of neoepitope-specific CD8+ T cells.FUNDINGNEYE Foundation; European Research Council; Lundbeck Foundation Fellowship; Carlsberg Foundation | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Cancer immunotherapy | |
650 | 4 | |a Immunology | |
650 | 4 | |a Melanoma | |
650 | 4 | |a T cells | |
650 | 4 | |a Therapeutics | |
650 | 7 | |a Antigens, Neoplasm |2 NLM | |
700 | 1 | |a Heeke, Christina |e verfasserin |4 aut | |
700 | 1 | |a Tvingsholm, Siri A |e verfasserin |4 aut | |
700 | 1 | |a Borch, Annie |e verfasserin |4 aut | |
700 | 1 | |a Draghi, Arianna |e verfasserin |4 aut | |
700 | 1 | |a Crowther, Michael D |e verfasserin |4 aut | |
700 | 1 | |a Carri, Ibel |e verfasserin |4 aut | |
700 | 1 | |a Munk, Kamilla K |e verfasserin |4 aut | |
700 | 1 | |a Holm, Jeppe Sejerø |e verfasserin |4 aut | |
700 | 1 | |a Bjerregaard, Anne-Mette |e verfasserin |4 aut | |
700 | 1 | |a Bentzen, Amalie Kai |e verfasserin |4 aut | |
700 | 1 | |a Marquard, Andrea M |e verfasserin |4 aut | |
700 | 1 | |a Szallasi, Zoltan |e verfasserin |4 aut | |
700 | 1 | |a McGranahan, Nicholas |e verfasserin |4 aut | |
700 | 1 | |a Andersen, Rikke |e verfasserin |4 aut | |
700 | 1 | |a Nielsen, Morten |e verfasserin |4 aut | |
700 | 1 | |a Jönsson, Göran B |e verfasserin |4 aut | |
700 | 1 | |a Donia, Marco |e verfasserin |4 aut | |
700 | 1 | |a Svane, Inge Marie |e verfasserin |4 aut | |
700 | 1 | |a Hadrup, Sine Reker |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 132(2022), 2 vom: 18. Jan. |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
773 | 1 | 8 | |g volume:132 |g year:2022 |g number:2 |g day:18 |g month:01 |
856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI150535 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 132 |j 2022 |e 2 |b 18 |c 01 |